

MARKED DEPLETION OF GLYCOSYLATION SITES IN HIV-1 gp120 UNDER SELECTION  
PRESSURE BY THE MANNOSE-SPECIFIC PLANT LECTINS OF *HIPPEASTRUM* HYBRID AND  
*GALANTHUS NIVALIS*

Jan Balzarini, Kristel Van Laethem, Sigrid Hatse, Matheus Froeyen, Els Van Damme, Anders  
Bolmstedt, Willy Peumans, Erik De Clercq, and Dominique Schols

*Rega Institute for Medical Research, K.U.Leuven, B-3000 Leuven (J.B., K.V.L., S.H., M.F., E.D.C.,  
D.S.); University Hospitals Leuven, B-3000 Leuven (K.V.L.); Department of Clinical Virology,  
University of Göteborg, Sweden (A.B.), Department of Molecular Biotechnology, RUGent, B-9000  
Gent, Belgium (E.V.D., W.P.)*

Running title: Depletion of glycosylation sites in HIV gp120 by plant lectins

Address correspondence to: Prof. J. Balzarini, Rega Institute for Medical Research,

Minderbroedersstraat 10, B-3000 Leuven, Belgium. E-mail: [jan.balzarini@rega.kuleuven.ac.be](mailto:jan.balzarini@rega.kuleuven.ac.be)

Number of text pages: 26

Number of tables: 4

Number of figures: 3

Number of references: 41

Number of words in the Abstract: 198

Number of words in the Introduction: 684

Number of words in the Discussion: 2,446

#### Abbreviations

HHA, *Hippeastrum hybrid* agglutinin; GNA, *Galanthus nivalis* agglutinin; CA, *Cymbidium hybrid* agglutinin; LOA, *Listera ovata* agglutinin; NPA, *Narcissus pseudonarcissus* agglutinin; FIPV, feline infectious peritonitis virus; SARS, severe acute respiratory syndrome; CV-N, Cyanovirin; PCR, polymerase chain reaction; DS-5000, dextran sulfate-5000; CS, cell suspension; SN, supernatant; WT, wild-type

## ABSTRACT

The plant lectins from *Hippeastrum* hybrid (HHA) and *Galanthus nivalis* (GNA) are 50,000 D tetramers showing specificity for  $\alpha$ -(1,3) and/or  $\alpha$ -(1,6)-mannose oligomers. They inhibit HIV-1 infection at an 50% effective concentration of 0.2-0.3  $\mu$ g/ml. Escalating HHA or GNA concentrations (up to 500  $\mu$ g/ml) led to the isolation of three HIV-1(III<sub>B</sub>) strains in CEM T-cell cultures that were highly resistant to HHA and GNA, several other related mannose-specific plant lectins and the monoclonal antibody 2G12, modestly resistant to the mannose-specific cyanovirin which is derived from a blue-green alga, but fully susceptible to other HIV entry inhibitors as well as HIV reverse transcriptase inhibitors. These mutant virus strains were devoid of up to seven or eight out of 22 glycosylation sites in the viral envelope glycoprotein gp120 due to mutations at the N- or T/S-sites of the N-glycosylation motifs. In one of the strains, a novel glycosylation site was created near a deleted glycosylation site. The affected glycosylation sites were predominantly clustered in regions of gp120 that are not involved in the direct interaction with either CD4, CCR5, CXCR4 or gp41. The mutant viruses, containing the deleted glycosylation sites, were markedly more infectious in CEM T-cell cultures than wild-type virus.

## Introduction

The entry of HIV into host cells is mediated by the viral envelope glycoproteins gp120 and gp41 that are non-covalently bound to each other. Five variable regions (V1-V5) interspersed by more conserved amino acid sequences have been identified in gp120 (Leonard et al., 1990; Gallaher et al., 1995). The conserved gp120 regions form structures important for interaction with the gp41 ectodomain, and the cellular (co-)receptors such as CD4, CXCR4 and CCR5. Several epitopes on gp120 have been identified by different (monoclonal) neutralizing antibodies (Schønning et al., 1996; Trkola et al., 1996; Kwong et al., 1998; Rizzuto et al., 1998; Wyatt et al., 1998; Scanlan et al., 2002). Both conserved and variable regions of gp120 are extensively glycosylated (Geyer et al., 1988; Mizuochi et al., 1988a,b). It is thought that the variability of glycosylation of the gp120 surface may likely modulate the immunogenicity of gp120, which is the main target for neutralizing antibodies (Nabs) that appear during natural infection (Oloffson & Hansen, 1998; Losman et al., 2001). Recently, Wei and colleagues (2003) showed that Nabs directed towards HIV gp160 were able to force the virus to replace the neutralisation-sensitive phenotype by successive populations of Nab-resistant virus strains. Indeed, during the progress of virus infection in HIV-infected individuals, gp120 mutates rapidly, primarily at glycosylation sites, resulting in a change of the glycan shield on the surface of the virus, thus affording some immunological escape. This mechanism allows the virus to persist in the presence of an evolving antibody repertoire.

In contrast with Nabs, plant lectins are a class of proteins that bind to carbohydrates and are of non-immune origin (for an overview, see Van Damme et al., 1998; Sharon & Lis, 2003). They precipitate polysaccharides and glycoproteins and are usually di- or oligovalent, i.e. each lectin molecule has at least two or more carbohydrate binding sites. The large majority of lectins recognize primarily mannose, glucose, galactose, N-acetylglucosamine, N-acetylgalactosamine, fucose and N-acetylneuraminic (sialic) acid. In addition, they combine specifically with a variety of oligosaccharides composed of these monosaccharides. It has been shown that a number of plant lectins, in particular with specificity for mannose oligomers, display potent inhibitory activity against several viruses, such as human immunodeficiency virus (HIV) (Lifson et al., 1986; Muller et al., 1988; Weiler et al., 1990; Matsui et al., 1990; Balzarini et al., 1991, 1992; Animashaun et al., 1993), human cytomegalovirus

(HCMV) (Balzarini et al., 1991), and coronaviruses (i.e. feline corona virus (FIPV) and human corona virus (SARS)) (Balzarini et al., 2004a). Moreover, some of these plant lectins [i.e. Galanthus nivalis agglutinin (GNA) and Hippeastrum hybrid agglutinin (HHA)] were recently demonstrated to represent potential candidate drugs as anti-HIV microbicides; they lack mitogenic activity, do not lead to human blood cell agglutination, and show marked stability at relatively low pH and high temperatures for prolonged time periods (Balzarini et al., 2004b). Preincubation of cell-free HIV particles or persistently HIV-infected cells with these plant lectins resulted in a further potentiation of their antiviral efficiency by at least 10- to 20-fold. The plant lectins clearly interact with the entry of HIV into its target cell. Recently, we demonstrated that HIV-1 exposed to HHA or GNA for prolonged time periods in cell culture, acquired mutations in the gp120 envelope protein (Balzarini et al., 2004c). These mutations predominantly appeared at asparagine residues that are part of the N-glycosylation motifs. Thus, the mannose-specific plant lectins selected for a unique drug resistance profile mainly affecting the glycosylation pattern of the HIV envelope glycoprotein. Such specific drug-resistance profile has so far not been demonstrated for any other type of HIV entry inhibitor.

We have now unraveled the molecular basis of the profound resistance profile of HIV-1(III<sub>B</sub>) strains that were exposed for prolonged time periods (up to 88 passages) to the plant lectins HHA and GNA under dose-escalating drug regimens in which eventually drug concentrations as high as 1,000-fold the original EC<sub>50</sub> were reached (i.e. 500 µg/ml). The composition of the gp120 and gp41 envelope glycoproteins of such highly drug-exposed virus strains was characterized, their resistance/sensitivity profile against several HIV entry inhibitors examined and the infectiveness of the drug-resistant virus strains determined.

## Materials and Methods

**Test compounds.** The mannose-specific plant lectins from *Galanthus nivalis* (GNA), *Hippeastrum* hybrid (HHA), *Narcissus pseudonarcissus* (NPA), *Cymbidium* hybrid (CA) and *Listera ovata* (LOA) were derived and purified from these plants, as described before (Van Damme et al., 1987, 1988). UC-781 was obtained from Crompton Ltd. (Middlebury, CT). Tenofovir was from Gilead Sciences (Foster City, CA), AMD3100 from AnorMed (Langley, BC, Canada) and dextran sulfate-5000 from Sigma (St. Louis, MO). T20 (pentafuside, enfuvirtide) was kindly provided by AIDS Research Alliance (Los Angeles, CA) and cyanovirin (CV-N) by Dr. J.B. McMahon (National Institutes of Health, Bethesda, MD) and Dr. A. Bolmstedt (Göteborg, Sweden). The monoclonal antibody 2G12 was obtained from the Medical Research Council (MRC), Potter Bar, Hertfordshire, U.K.

**Cells.** Human T-lymphocytic CEM and SupT1 cells were obtained from the American Type Culture Collection (Rockville, MD) and persistently infected CEM/HIV-1 cells were obtained by exposing CEM cell cultures to wild-type HIV-1(III<sub>B</sub>) or mutant (GNA- or HHA-resistant) HIV-1 for 3 to 4 weeks. All cell lines mentioned were cultivated in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) (BioWittaker Europe, Verviers, Belgium), 2 mM L-glutamine and 0.075 M NaHCO<sub>3</sub>.

Human astrogloma U87 cells transfected with CD4 and either of the chemokine receptors/HIV-1 coreceptors CCR5 (U87.CD4.CCR5 cells) or CXCR4 (U87.CD4.CXCR4 cells) were kindly provided by Dr. D.R. Littman (Skirball Institute of Biomolecular Medicine, New York, NY) and were cultured in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% FBS, 0.01M HEPES buffer (Invitrogen), 0.2 mg/ml geneticin (G-418 sulfate) (Invitrogen) and 1 µg/ml puromycin (Sigma-Aldrich). Subcultivations were done every 2-3 days by digestion of the monolayers with trypsin/EDTA (Invitrogen).

**Viruses.** HIV-1(III<sub>B</sub>) was provided by Dr. R.C. Gallo & Dr. M. Popovic (at that time at the National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD).

**Selection and isolation of GNA- and HHA-resistant HIV-1 strains.** The procedure followed for the selection of drug-resistant virus mutants was essentially as recently described (26). Briefly, HIV-

1(III<sub>B</sub>) was added to CEM cell cultures in 48-well plates in the presence of 0.5 µg/ml GNA or 0.25 µg/ml HHA. For the generation of drug-resistant virus mutants, an increased drug concentration was administered when full cytopathicity was obtained in the previous cell culture. For the clinical isolate HIV-1/HE isolated from a Belgian patient and belonging to HIV-1 clade B, p24 production instead of virus-induced cytopathicity in the presence of the different concentrations of the test compounds was measured for each passage, before subculturing the virus-exposed cells and deciding on the dilution of the supernatants that had to be transferred.

**Antiretrovirus assays.** The methodology of the anti-HIV assays has been described previously (Balzarini et al., 2004b,c). Briefly, CEM cells ( $4.5 \times 10^5$  cells per ml) were suspended in fresh culture medium and infected with HIV-1 at 100 CCID<sub>50</sub> per ml of cell suspension. Then, 100 µl of the infected cell suspension were transferred to microplate wells, mixed with 100 µl of the appropriate dilutions of the test compounds, and further incubated at 37°C. After 4 to 5 days, giant cell formation was recorded microscopically in the CEM cell cultures. The 50% effective concentration (EC<sub>50</sub>) corresponds to the compound concentrations required to prevent syncytium formation by 50% in the virus-infected CEM cell cultures.

**Genotyping of the HIV-1 *env* region.** Proviral DNA was extracted from cell pellets using the QIAamp Blood Mini Kit (Qiagen, Hilden, Germany) as described before (Van Laethem et al., 2005). Both the gp120 and gp41 genes were included in this assay.

**Viral load determination.** The RNA viral load of virus supernatant samples was determined using VERSANT HIV-1 RNA 3.0 Assay (bDNA, Bayer HealthCare, Brussel, Belgium), as described by the Manufacturer. The p24 antigen was determined using the commercial assay kit from Perkin Elmer (Zaventem, Belgium).

**HIV entry PCR.** The U87.CD4.CXCR4 and U87.CD4.CCR5 cells were seeded in 24-well plates at  $5 \times 10^4$  cells per well and incubated overnight. Virus stocks (diluted to a p24 titer of 10,000 pg/ml) were treated with 500 U/ml of RNase-free DNase (Roche Molecular Biochemicals) for 1 hour at room temperature. Then, the cells in each well were infected with 1000, 500 or 250 pg/ml p24. To control for possible residual contamination of the viral inoculum with viral DNA, a parallel infection was carried out on the CCR5-transfected (CXCR4-negative) U87.CD4 cells. After incubation at 37°C

for 2 hours, the medium was aspirated, the cells were washed once with PBS and total DNA was extracted from the infected cells using the QIAamp DNA Mini Kit (QIAGEN). The DNA was eluted from the QIAamp spin columns in a final volume of 250  $\mu$ l elution buffer. Then, 10  $\mu$ l of each DNA sample was subjected to 36 cycles of HIV-1 LTR R/U5-specific and 33 cycles of  $\beta$ -actin-specific PCR on a Biometra T3 Thermocycler. Each cycle comprised a 45-sec denaturation step at 95°C, a 45-sec annealing step at 61°C and a 45-sec extension step at 72°C. The primers used were : LTR R/U5 sense primer 5'-GGCTAACTAGGGAACCCACTG-3' (nucleotides 496 to 516, according to the HIV-1 HXB-2 DNA sequence), LTR R/U5 antisense primer 5'-CTGCTAGAGATTTTCCACACTGAC-3' (nucleotides 612 to 635),  $\beta$ -actin sense primer 5'-TCTGGCGGCACCACCATGTACC-3' (nucleotides 2658 to 2679),  $\beta$ -actin antisense primer 5'-CGATGGAGGGGCCGACTCG-3' (nucleotides 2961 to 2980). The reaction mixtures contained PCR buffer (supplied with the enzyme), 200  $\mu$ M of each dATP, dGTP, dCTP and dTTP (Life Technologies), 0.4  $\mu$ M each of the sense and antisense primers and 0.5 U SuperTaq DNA polymerase (HT Biotechnology, Cambridge, England) in a total volume of 25  $\mu$ l. After gel electrophoresis through a 2% agarose gel, the amplified DNA fragments were visualized by ethidium bromide. In preliminary experiments, the exponential range of the PCR amplification curve was determined for both the HIV-1 LTR R/U5 and the  $\beta$ -actin PCRs by varying the amount of input DNA and the number of PCR cycles. Based on these experiments, appropriate conditions were chosen to perform the PCRs.



## Results

**Selection of HHA- and GNA-resistant HIV-1(III<sub>B</sub>) strains.** The plant lectins HHA and GNA were exposed to HIV-1(III<sub>B</sub>)-infected 1 ml-CEM cell cultures in 48-well microtiter plates at one- to two-fold their EC<sub>50</sub>. Every 3 to 4 days, the drug-exposed cultures were subcultured by transferring 100 µl of supernatant or cell suspension to freshly prepared 900 µl-CEM cell cultures containing ~ 3-4 x 10<sup>5</sup> cells. As soon as full cytopathic effect (giant cell formation) was recorded microscopically, a higher drug concentration was added at the next passage of the cell cultures. To reach a concentration of 500 µg/ml GNA or HHA to be added to the virus-infected cell cultures after the dose-escalating procedure (that is a drug concentration that is 3 orders of magnitude higher than the EC<sub>50</sub>), a minimum of 65 to 90 subcultivations were required (Fig. 1). GNA and HHA resistance was also selected against a clinical HIV-1 isolate (designated HIV-1/HE) derived from a Belgian AIDS patient (29). The treatment modalities are depicted in Table 1. Instead of recording virus-induced cytopathicity for each subcultivation, p24 levels in the cell culture supernatants were determined to monitor virus breakthrough (Table 1).

**Mutational analysis of the HIV-1 strains isolated upon escalating HHA and GNA drug exposure.** The gp120 and gp41 genes of two HIV-1(III<sub>B</sub>) strains isolated after HHA- and one HIV-1(III<sub>B</sub>) strain isolated after GNA-escalating drug administration to the HIV-1-infected cell cultures were sequenced and analysed for the presence of mutations in comparison with the envelope gene the original wild-type HIV-1(III<sub>B</sub>) that had also been subcultured for a similar number of passages in the absence of the plant lectins. A variety of mutations at N-glycosylation sites in gp120 were detected in the three drug-exposed virus strains, whereas none of the N- glycosylation sites in gp41 were affected. At least 8 glycosylation sites were mutated in the two HHA-exposed and independently selected virus strains, and 7 glycosylation sites were affected in the GNA-exposed virus strain (Table 2). The mutations occurred either directly at N-sites of gp120 (2 out of 8 mutations in HIV-1/HHA-500SN; 3 out of 8 mutations in HIV-1/HHA-500CS; 3 out of 7 mutations in HIV-1/GNA-500CS) or, predominantly, at T- or S-sites of gp120 that are part of the N-glycosylation motifs (Table 2). The mutations were preferentially targeted at the asparagine residues that carried a high mannose type

glycan (74% of the cases), rather than at those asparagines that carried a complex-type glycan (26% of the cases). Interestingly, in the HIV-1/HHA-500SN strain, one mutation at amino acid position 188 from T to N resulted in the annihilation of the 186N glycosylation site but created a new glycosylation site at 188N: since the amino acid at 190 consists of S, a new glycosylation motif, 188NTS160, was thus created. Given the fact that gp120 of our HIV-1(III<sub>B</sub>) strain contains 22 potential N-glycosylation sites, the three virus strains isolated in the presence of HHA or GNA contained a markedly lower amount of glycans in their envelope glycoprotein gp120 than wild-type virus (i.e., 64 to 68% of the wild-type glycans).

To reveal whether the plant lectins also select for deletions in gp120 N-glycosylation sites of a clinical HIV-1 strain isolated from a Belgian patient (designated HIV-1/HE), GNA and HHA were administered to the virus in a dose-escalating manner as performed for the laboratory HIV-1(III<sub>B</sub>) strain and shown in Table 1. Instead of scoring virus breakthrough at each subcultivation by estimating microscopically visible giant cell formation, the p24 levels produced in the CEM cell cultures were measured after each passage as a parameter for virus production in the presence of the different compound concentrations. The treatment schedule and p24 measurements are depicted in Table 1. The clinical HIV-1/HE isolate is intrinsically less sensitive to both plant lectins. When the N-glycosylation sites of gp120 of HIV-1/HE were determined and compared with those on gp120 of HIV-1(III<sub>B</sub>), five N-glycosylation sites were absent (i.e. a 142SSGHMIME150 deletion resulting in loss of the 141NSS143 glycosylation motif, a N230D mutation, a N234 deletion; a S291P mutation resulting in the loss of the 289NQP291 glycosylation motif, and a N356 deletion) but three new glycosylation sites were created [i.e. K130NCT132, T413NET415 and a glycosylation motif created by the insertion of the dipeptide ET after N432. However, at 17 passages upon the administration of HHA and GNA escalating concentrations, three N-glycosylation sites in HIV-1/HE were affected (i.e. 130NCT132 was converted to 130DCT132; 276NFT278 was converted to 276NFM278 and 397NST399 was converted to a mixture of 397NDST399). Thus, plant lectins exposed to a clinical HIV strain in a dose-escalating manner select for mutations in the glycosylation motifs of gp120 as also found for the laboratory HIV-1(III<sub>B</sub>) strain.

### **Sensitivity of mutant virus isolates against plant lectins and other HIV entry inhibitors.**

The mutant HIV-1 isolates that were isolated after dose-escalating exposure to HHA and GNA were evaluated for their sensitivity against several mannose-specific plant lectins, the mannose-specific blue-green alga (cyanobacterium)-derived lectin cyanovirin and other entry inhibitors including the adsorption inhibitor dextran sulphate (DS-5000), the gp41-targeting T-20, and the CXCR4 antagonist AMD3100. The three virus isolates proved highly resistant to the inhibitory effects of HHA and GNA (degree of resistance: 100- to 1,000-fold). They also showed cross-resistance to other mannose-specific plant lectins such as those derived from LOA (*Listera Ovata* agglutinin), CA (*Cymbidium* agglutinin) and NPA (*Narcissus pseudonarcissus* agglutinin) (Table 2). The three mutant virus strains were only modestly (~ 5- to 30-fold) resistant to cyanovirin, and did not show cross-resistance against any of the other viral entry inhibitors (i.e. DS-5000, AMD3100, T-20) (Table 2). Also, the reverse transcriptase inhibitors UC-781 and tenofovir retained their full inhibitory activity against the mutant virus strains. Finally, the monoclonal antibody 2G12 that binds to a HIV-1 oligomannose epitope of gp120 completely lost its inhibitory potential against the mutant virus strains (Table 3).

**Degree of infectivity of plant lectin-resistant HIV-1 strains versus wild-type virus.** The infectivity potential of the three mutant virus strains was determined in comparison with that of the wild-type parental HIV-1(III<sub>B</sub>) strain (Table 4). To this end, the amount of p24, viral RNA and CCID<sub>50</sub> was determined for each virus. The HIV-1/GNA-500CS strain proved approximately 30-fold more infectious than wild-type when the infectivity (CCID<sub>50</sub>) was calculated relative to the RNA content. The increased infectivity normalised to the p24 content confirms our findings of the increased infectivity normalised to virus RNA content (Table 4). The HIV-1/HHA-500SN and HIV-1/HHA-500CS virus strains were also more infectious than wild-type virus (11- to 13-fold for the former, and 7- to 11-fold for the latter virus strain) (Table 4).

Since some mutations in gp120 have been reported to enable co-receptor switch of the mutant viruses, we performed infection experiments of wild-type and the mutant virus strains in both a CXCR4 and a CCR5 expressing U 87 cell line. The different mutant virus strains and the parental wild-type virus, were exposed to the U 87 cell cultures at virus inocula that contained equal amounts of p24 (i.e. 1000, 500 and 250 pg p24). A semiquantitative HIV-1 LTR R/U5-specific PCR on total DNA was then

performed at 2 h after infection of U87.CD4.CCR5 cells (lanes 13-16) or U87.CD4.CXCR4 cells (lanes 1-12) with wild-type HIV-1 (lanes 1-3, 13), HIV-1/GNA-500CS (lanes 4-6, 14), HIV-1/HHA-500CS (lanes 7-9, 15) and HIV-1/HHA-500SN (lanes 10-12, 16) (Fig. 2). No DNA signal could be measured in lanes 13 to 16 where the wild-type and the three mutant HIV-1(III<sub>B</sub>) strains had been exposed to CD4- and CCR5-expressing (CXCR4-negative) U87 cell cultures. However, appearance of viral DNA occurred when the wild-type and the three mutant virus strains were exposed to CD4- and CXCR4-expressing U87 cell cultures. The most infectious mutant virus strain (HIV-1/GNA-500CS) (Table 4) gave also the strongest DNA signal in the cell cultures at 2 hr post infection (lanes 4-6). The least infectious (wild-type) virus strain gave the poorest DNA signal (lanes 1-3), and the intermediate infectious virus strains (HIV-1/HHA-500CS and HIV-1/HHA-500SN) (lanes 7-9 and 10-12) led to an intermediate DNA signal (Fig. 2). For each individual virus strain, there was also a dose-dependent decrease in DNA signal, depending the amount of initial p24 used in the infection experiment (i.e. 1000, 500 or 250 pg p24) (Fig. 2). The corresponding PCR signal of the non-related  $\beta$ -actin gene was comparable in all conditions (Fig. 2). However, although there seemed to be a correlation between the degree of infectiveness of the virus strains and the intensity of PCR signal of viral DNA synthesis, it should be kept in mind that accurate quantitation of virus entry and synthesis of the very first viral DNA products can only be achieved by real-time PCR analysis.

## Discussion

In marked contrast with the glycosylation sites of the gp120 envelope glycoprotein of the mutant virus strains, the four glycosylated asparagines of the gp41 fusion glycoprotein were not affected in any of the three HHA- and GNA-resistant virus isolates. Since these glycans are complex types of unknown nature (2), the highly mannose-specific plant lectins used in this study may not be able to efficiently recognize these glycans on gp41. These findings demonstrate that plant lectins are targeting gp120, but not gp41 to exert their antiviral activity.

Although the complex sugar type glycosylation sites in HIV-1 gp120 [11 out of 22 sites in the HIV-1(III<sub>B</sub>) strain used in this study] are slightly more abundant than the high-mannose glycosylation sites (Leonard et al., 1990; Gallaher et al., 1995), it is striking that the vast majority of mutations (~75%) that appear under plant lectin pressure predominantly occur at N-glycosylation sites that bear high-mannose type sugar oligomers, and not the complex type sugar moieties. However, since 90% of the complex oligosaccharides in gp120 are assumed to be fucosylated and 94% of them reported to be sialylated (Leonard et al., 1990; Hart et al., 2002), it is likely that efficient recognition of these complex oligomer sugar structures by the mannose-specific plant lectins is hampered by the presence of additional non-mannose like sugars. Although cross-resistance to other mannose-specific plant lectins had not been surprising (resistance degree ranging from 100 to 1,000), it was interesting to notice that the blue-green alga-derived mannose-specific cyanovirin (Boyd et al., 1997; Bolmstedt et al., 2001) still retained marked antiviral activity (EC<sub>50</sub>: 0.077-0.43 µg/ml; resistance degree ranging from 5 to 30) (Table 2) against the mutant virus strains. These findings point to subtle differences in mannose oligomer specificities between cyanovirin and the mannose-specific plant lectins. In fact, we also selected for drug resistance of HIV-1(III<sub>B</sub>) against the cyanobacterium-derived mannose-specific cyanovirin. A virus isolate, recovered after 35 subcultivations (in the presence of stepwise drug-escalating concentrations using 0.025, 0.05, 0.10, 0.4, 0.60, 0.75 and eventually 1 µg cyanovirin/ml) contained a mixture of Y/N301N and a S334N, N339S and N448S mutation in its gp120. This virus strain displayed 12-fold resistance to cyanovirin in CEM cell cultures. Thus, also another mannose-specific lectin that was not derived from a plant, but from a procaryotic microorganism, select for

mutations in gp120 at N-glycosylation sites or at NXS glycosylation motifs, as also observed for mannose-specific plant lectins. These observations are in agreement with recent findings of Witvrouw et al. that cyanovirin and also the mannose-specific concanavalin plant lectin select for deletions of glycosylation sites in HIV-1 gp120 (Witvrouw et al., 2005).

The selection of plant lectin-resistant HIV-1(III<sub>B</sub>) strains has been performed by monitoring giant cell formation as a parameter to decide whether the compound concentration should be increased or maintained during the next subcultivation. Since changes in the glycosylation pattern of gp120 can modify the capacity of HIV-1 strains to form syncytia, independently from its infectivity characteristics, it cannot be excluded that there occurred some bias in the representativeness of the mutant virus isolates during the selection process. However, when selecting for plant lectin resistance against the clinical HIV-1/HE isolate, p24 production in the cell culture medium was determined before each subcultivation instead of syncytia formation in the cell cultures. As found for the HIV-1(IIIB) resistance selection experiments, the glycosylation of gp120 of the drug-exposed clinical virus isolate was also clearly affected. One of the mutations resulted in the annihilation of the N-glycosylation site at amino acid position 276 that was also observed in the plant lectin-resistant HIV-1/HHA 500CS strain (Table 2).

The removal of several glycosylation sites in gp120 resulted in more infectious virus compared with the parental wild-type HIV-1. The markedly increased infectiveness of the mutant viruses was observed relative to the RNA content of the virus particles, and it was shown that the more infectious the mutant virus strains, the more abundant (and faster) the very first DNA transcripts appear in the virus-exposed cells. It can be hypothesized that the increased infectiveness of the mutant virus strains relative to the wild-type may be related to a higher affinity of mutant gp120 for its (co)receptor and thus a likely increased efficiency of the virus to enter the target cell. It has indeed been shown earlier that a mutation in the N-glycosylation site of the V3 loop can lead to co-receptor switch due to increased affinity for the receptor CXCR4 (Pollakis et al., 2001; Polzer et al., 2003). This increased affinity has been ascribed to a markedly increased exposure of the positive charges of the gp120 V3 loop (previously largely covered by the glycan on amino acid position 301) to the negatively charged CXCR4 receptor. It is so far unclear which particular mutation(s) in the gp120 of the mutant viruses is

responsible for this phenomenon. However, the infection experiments with the mutant virus strains aimed at detecting the very first DNA transcription products, revealed that no proviral DNA could be detected when these virus strains were exposed to CD4- and CCR5-expressing U87 cells, revealing that no co-receptor switch from CXCR4 to CCR5 had occurred for the mutant viruses.

The interaction of gp120 with CD4 is based upon contacts with one amino acid of the V1/V2 stem, loop LD (279-282), the  $\beta$ 15- $\alpha$ 3 excursion (365-368 and 369-372), the  $\beta$ 20- $\beta$ 21 hairpin (422-427 and 430-435), the  $\beta$ 23 strand (451-457) and the  $\beta$ 24- $\alpha$ 5 connection (464-470 and 475-484) and the interaction of gp120 with CXCR4/CCR5 involves the amino acids of the V3 loop (296-330), the bridging sheet containing  $\beta$ 2 and  $\beta$ 3, the  $\beta$ 20 and  $\beta$ 21 strands, and the amino acids R419, K421 and Q422 at the end of  $\beta$ 19 (3,8) (Fig. 3). Except for the glycosylated N301 amino acid found in the V3 domain of gp120, no mutations were found in the areas that interact with the (co)receptors. It also explains why the mannose-specific plant lectins are not able to prevent gp120/CD4 binding, but instead inhibit the virus fusion process at a stage that follows binding of the virus to the target cells (Matsui et al., 1990; Weiler et al., 1990).

Several investigators have studied the effect of mutations in gp120 on viral infectivity and (co)receptor interaction. Lee and colleagues (1992) mutated each of the 24 asparagines in HIV-1 gp120 that are part of the glycosylation motif N-X-T/S. They found that all these single mutants kept their ability to infect SupT1 cells and form giant cells, although the infectivity was somewhat impaired by mutations at amino acid positions 88, 141, 160, 197, 262 and 276. The authors showed that this impaired infectivity was due to the lack of the glycans in gp120 except for amino acid 160 where it was shown that the impaired infectivity was due to the amino acid change (N $\rightarrow$ Q) as such rather than to the deletion of the glycan moiety. The amino acids 88 and 276, but not the other asparagine mutations that showed impaired infectivity, were mutated in one or two of the plant lectin-resistant mutant virus strains. However, given the increased infectivity of our mutant virus strains, this phenomenon can not be accounted to amino acid mutations 88 or 276.

Hemming *et al.* (1994) performed site-directed mutagenesis on the C-terminal N406, N448 and N463 that are located in the CD4 binding area of gp120. When abolished all together, the absence of

these 3 glycosylation sites had no effect on syncytia induction and thus are dispensable for an efficient CD4 binding and subsequent viral fusion. The C-terminal N-glycosylation sites were not affected in the plant lectin-resistant virus strains.

Lack of the N-linked glycan at N186 in the V1 loop had also no effect on infectivity in cell culture (Gram et al., 1994). However, since this virus mutant was more resistant to neutralisation by mabs to the V3 loop and by sCD4, it was concluded that the N-linked glycan in V1 may modulate the tri-dimensional conformation of gp120 without changing the overall functional integrity of the molecule.

Interestingly, Trkola et al. (1996) and Scanlan et al. (2002) investigated mutations on gp120 at N295, N332, N339, N386 and N392 by N→A substitutions, resulting in markedly decreased affinity for mab 2G12 binding. This neutralizing anti-HIV-1 antibody recognizes a cluster of  $\alpha 1 \rightarrow 2$  mannose residues of oligomannose glycans on the outer phase of gp120. Whereas N339 and N386 proved less critical for 2G12 binding, and may rather play an indirect role in maintaining the epitope conformation, N295 and N392 were crucial for 2G12 epitope binding. Interestingly, all five N positions in gp120 were also found to be mutated in one or several of our plant lectin-resistant mutant virus strains. As it was also shown that cyanovirin competed with 2G12 for these interaction sites and prevents 2G12 binding to this epitope on gp120, it is likely that the plant lectins may recognise this region of the gp120 molecule as well. These conclusions are also in line with the resistance of our mutant virus strains against the mab 2G12. Moreover, since it has been suggested that 2G12 antibodies may have a high potential to prevent natural HIV-1 infection *in vivo* (Wolbank et al., 2003), it would be interesting to further explore plant lectins in this respect.

In the HIV-1/HHA-500SN strain, there was one glycosylation site (at position 186) in the V1/V2 stem of gp120 deleted but replaced by a novel glycosylation site (at position 188), thus only 2 amino acids downstream of the original (deleted) glycosylation site. The significance of this observation is currently unclear (Fig. 3, panel A, green ball in ribbon structure).

The annihilation of clustered glycosylation sites under plant lectin pressure predominantly occurred for all 3 mutant virus strains at the top of the inner domain (near the gp41 binding site), and, except for the mutation in the V3 loop, the left upper half and the right side of the outer domain (Fig. 3).



Given the multivalent nature of the plant lectins (GNA is a tetramer with 12 mannose-binding sites), it would now be interesting to co-crystallize gp120 with the plant lectins to reveal the interaction points of these proteins with the gp120 glycans. It may be assumed that the conformational changes in gp120 that need to occur sequentially during the fusion process may be inhibited by complexation of gp120 with the plant lectins.

The presence of the sugar moieties in gp120 may not appear necessary to afford efficient virus-cell fusion, since the mutant virus strains were more infectious than the wild-type virus. Therefore, it can be hypothesized that the more glycosylation sites are removed from gp120, the easier the fusion process may proceed and the more the virus would display resistance to the plant lectins. However, additional studies should address the conformational changes induced by the plant lectins in the viral envelope glycoproteins (particularly gp120) and also any potential conformational changes in the gp120 envelope that may occur upon mutation of the glycosylated asparagine sites.

The pressure that plant lectins exert on the virus to mutate its gp120 envelope in cell culture resulting in changes of its glycan shield may be somewhat comparable with the pressure neutralizing antibodies exert during the progress of virus infection in HIV-infected individuals (Wei et al., 2003). Indeed, it has been shown that also *in vivo*, the envelope gene of HIV-1 rapidly mutates and primarily at glycosylation sites of gp120. This phenomenon, observed in HIV-infected individuals, results in a change of the glycan shield on the surface of the virus and creates a physical block to the binding of neutralizing antibody. This mechanism of immunological escape markedly contributes to the HIV persistence in the face of an evolving antibody repertoire. It can, therefore, be speculated that plant lectins, if ever used to treat HIV-infected individuals, may markedly hamper the potential of HIV to escape the immune surveillance.

Whereas the virus seems to need to continuously change its envelope glycan shield in response to the immune system, lectins may force the virus to a very limited pattern of successful escape mutations. Plant lectin-exposed HIV may get caught by two non-compatible escape pathways by which the virus may run-out of valuable options to escape drug pressure and immunological pressure at the same time. Therefore, one interesting possibility would be to immunize HIV-infected individuals with gp120 epitopes that are likely to appear under plant lectin pressure (thus lacking several parts of the

glycan shield of gp120) after which drug pressure should be put on the virus. Then, in an attempt to escape from the plant lectin pressure, the virus may try to abolish part of its sugar content on gp120, allowing the immune system to more efficiently tackle these mutant gp120-containing virus strains. It would seem justified to further explore this hypothesis. Indeed, Bolmstedt and colleagues reported that immunisation of mice with HIV-1 gp120 lacking the N336 glycosylation signal (mutant 306NNA308) in the V3 loop (the gp120 amino acid numbering of the authors corresponds to 339NNA341 according to our numbering in Table 2 and Fig. 3) resulted in higher serum IgG-binding titers to HIV-1 gp120 (immunisation with DNA-encoding mutant HIV-1 env) than when wild-type HIV-1 gp120 was used (immunisation through DNA-encoding wild-type HIV-1 env) (Bolmstedt et al., 2002). These authors could also demonstrate that no differences in neutralisation titers were obtained in mice immunized against wild-type or mutant HIV-1 env DNA, concluding that the N336 mutant gp120 resulted in immunisation against a non-neutralisation epitope. However, it was clear that, by changing the glycosylation pattern of HIV-1 gp120, more efficient antibody responses as well as T-cell responses were directed to wild-type gp120 (Bolmstedt et al., 2002). These observations are also in agreement with earlier reports that HIV-1 gp120 protein glycosylation can be a primary modifier of virus antigenicity that is susceptible to the host immune response (Schønning et al., 1996).

In conclusion, plant lectins with absolute preference for mannose oligomers efficiently inhibit HIV replication in cell culture by preventing entry of the virus into its target cells. From this perspective, the plant lectins may qualify as potential anti-HIV microbicide drug candidates. The plant lectins select drug-resistant virus strains that retain full sensitivity to other viral entry inhibitors and have accumulated mutations in the gp120 that result in a dramatically decreased degree of N-glycosylation and a concomitantly increased infectiveness. In this respect, these compounds can be considered as rather unique in terms of specificity for their molecular target as compared to other reported viral entry inhibitors. Given the importance of a rapidly evolving glycan shield at the HIV envelope to continuously escape the immune surveillance, plant lectins may play an important role to force the virus to convert to a gp120 phenotype that cannot properly escape from the immune system, and this may in turn result in a more efficient elimination of infectious HIV from the body.

### **Acknowledgments**

We are grateful to Mrs. Ann Absillis and Mr. Yoeri Schrooten for excellent technical assistance and Mrs. Christiane Callebaut for dedicated editorial assistance.

## References

- Animashaun T, Mahmood N, Hay AJ, Hughes RC (1993) Inhibitory effects of novel mannose-binding lectins on HIV-infectivity and syncytium formation. *Antiviral Chem Chemother* **4**: 145-153.
- Balzarini J, Schols D, Neyts J, Van Damme EJM, Peumans W, De Clercq E (1991)  $\alpha$ -(1-3)- and  $\alpha$ -(1-6)-D-mannose-specific plant lectins are markedly inhibitory to human immunodeficiency virus and cytomegalovirus infections in vitro. *Antimicrob Agents Chemother* **35**: 410-416.
- Balzarini J, Neyts J, Schols D, Hosoya M, Van Damme E, Peumans W, De Clercq E (1992) The mannose-specific plant lectins from *Cymbidium* hybrid and *Epipactis helleborine* and the (N-acetylglucosamine)n-specific plant lectin from *Urtica dioica* are potent and selective inhibitors of human immunodeficiency virus and cytomegalovirus replication *in vitro*. *Antiviral Res* **18**: 191-207.
- Balzarini J, Vijgen L, Keyaerts E, Van Damme E, Peumans W, De Clercq E, Egberink H, Van Ranst M (2004a) Mannose-specific plant lectins are potent inhibitors of coronavirus infection including the virus causing SARS. 17th International Conference on Antiviral Research, Tucson, Arizona, USA, 2 May-6 May 2004. *Antiviral Res* **62**: A76, no. 122.
- Balzarini J, Hatse S, Vermeire K, Princen K, Aquaro S, Perno C-F, De Clercq E, Egberink H, Van den Mooter G, Peumans W, Van Damme E, Schols D (2004b) Mannose-specific plant lectins from the *Amaryllidaceae* family qualify as efficient microbicides for prevention of human immunodeficiency virus infection. *Antimicrob Agents Chemother* **48**: 3858-3870.
- Balzarini J, Van Laethem K, Hatse S, Vermeire K, De Clercq E, Peumans W, Van Damme EJM, Vandamme A-M, Bolmstedt A, Schols D (2004c) Profile of resistance of human immunodeficiency virus to mannose-specific plant lectins. *J Virol* **78**: 10617-10627.
- Bolmstedt AJ, O'Keefe BR, Shenoy, SR, McMahon JB, Boyd MR (2001) Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. *Mol Pharmacol* **59**: 949-954.

- Bolmstedt A, Hinkula J, Rowcliffe E, Biller M, Wahren B, Olofsson S (2002) Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. *Vaccine* **20**: 397-405.
- Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina II JH, Buckheit Jr RW, Nara PL, Pannell LK, Sowder II RC, Henderson LE (1997) Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. *Antimicrob Agents Chemother* **41**: 1521-1530.
- Gallaher WR, Ball JM, Garry RF, Martin-Amedee AM, Montelaro RC (1995) A general model for the surface glycoproteins of HIV and other retroviruses. *AIDS Res Human Retroviruses* **11**: 191-202.
- Geyer H, Holschbach C, Hunsmann G, Schneider J (1988) Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120. *J Biol Chem* **263**: 11760-11767.
- Gram GJ, Hemming A, Bolmstedt A, Jansson B, Olofsson S, Akerblom L, Nielsen JO, Hansen JE (1994) Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. *Arch Virol* **139**: 253-261.
- Hart ML, Saifuddin M, Uemura K, Bremer EG, Hooker B, Kawasaki T, Spear GT (2002) High mannose glycans and sialic acid on gp120 regulate binding of mannose-binding lectin (MBL) to HIV type 1. *AIDS Res Human Retrovir* **18**: 1311-1317.
- Hemming A, Bolmstedt A, Jansson B, Hansen JE, Travis B, Hu SL, Olofsson S (1994) Identification of three N-linked glycans in the V4-V5 region of HIV-1 gp 120, dispensable for CD4-binding and fusion activity of gp 120. *Arch Virol* **134**: 335-344.
- Kraulis PJ (2001) MOSCRIPT: a program to produce both detailed and schematic plots of protein structures. *J Appl Crystallography* **24**: 946-950.
- Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. *Nature* **393**: 648-659.

- Lee WR, Syu WJ, Du B, Matsuda M, Tan S, Wolf A, Essex M, Lee TH (1992) Nonrandom distribution of gp120 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. *Proc Natl Acad Sci USA* **89**: 2213-2217.
- Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. *J Biol Chem* **265**: 10373-10382.
- Lifson JD, Coutre S, Huang E, Engleman E (1986) Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV) infectivity and virus-induced cell fusion. *J Exp Med* **164**: 2101-2106.
- Losman B, Bolmstedt A, Schönning K, Björndal A, Westin C, Fenyö EM, Olofsson S (2001) Protection of neutralization epitopes in the V3 loop of oligomeric human immunodeficiency virus type 1 glycoprotein 120 by N-linked oligosaccharides in the V1 region. *AIDS Res Human Retrovir* **17**: 1067-1076.
- Matsui T, Kobayashi S, Yoshida O, Ishii S, Abe Y, Yamamoto N (1990) Effects of succinylated concanavalin A on infectivity and syncytial formation of human immunodeficiency virus. *Med Microbiol Immunol* **179**: 225-235.
- Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, Feizi T (1988a) Carbohydrate structures of the human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. *Biochem J* **254**: 599-603.
- Mizuochi T, Spellman MW, Larkin M, Solomon J, Basa LJ, Feizi T (1988b) Structural characterization by chromatographic profiling of the oligosaccharides of human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells. *Biomed Chromatogr* **2**: 260-270.
- Muller WEG, Renneisen K, Kreuter MH, Schroder HC, Winker I (1988) The D-mannose-specific lectin from *Gerardia savaglia* blocks binding of human immunodeficiency virus type 1 to H9 cells and human lymphocytes *in vitro*. *J Aids* **1**: 453-458.

- Oloffson S, Hansen JE (1998) Host cell glycosylation of viral glycoproteins – a battlefield for host defence and viral resistance. *Scand J Infect Dis* **30**: 435-440.
- Pollakis G, Kang S, Kliphuis A, Chalaby MIM, Goudsmit J, Paxton WA (2001) N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. *J Biol Chem* **276**: 13433-13441.
- Polzer S, Thorsden I, Schmitz H, Schreiber M (2003) The role of HIV gp120 and CXCR4 N-glycans in HIV pathogenesis. The First International Meeting on Glycovirolgy: Viruses and Glycans, Göteborg, Sweden, 15-18 June 2003, abstract no O11.
- Rizzuto CD, Wyatt R, Hernández-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J (1998) A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. *Science* **280**: 1949-1953.
- Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of  $\alpha$ 1 $\rightarrow$ 2 mannose residues on the outer face of gp120. *J Virol* **76**: 7306-7321.
- Schønning K, Jansson B, Olofsson S, Hansen JES (1996) Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1. *J Gen Virol* **77**: 753-758.
- Sharon N, Lis H (Eds) (2003) Lectins, 2nd Edition, pp 1-452. Kluwer Academic Publishers, Dordrecht, Boston, London.
- Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore JP, Katinger H (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. *J Virol* **70**: 1100-1108.
- Van Damme EJM, Allen AK, Peumans WJ (1987) Leaves of the orchid twayblade (*Listera ovata*) contain a mannose-specific lectin. *Plant Physiol* **85**: 566-569.
- Van Damme EJM, Allen AK, Peumans WJ (1988) Related mannose-specific lectins from different species of the family Amaryllidaceae. *Physiol Plant* **73**: 52-57.

- Van Damme EJM, Peumans WJ, Pusztai A, Bardocz S (eds) (1998) Handbook of Plant Lectins: Properties and Biomedical Applications, pp 1-451. John Wiley & Sons, Chichester, New York.
- Van Laethem K, Schrooten Y, Lemey P, Van Wijngaerden E, De Wit S, Van Ranst M, Vandamme A-M (2005) A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene. *J Virol Methods* **123**: 25-34.
- Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2003) Antibody neutralization and escape by HIV-1. *Nature* **422**: 307-312.
- Weiler BE, Schroder HC, Stefanovich V, Stewart D, Forrest JM, Allen LB, Bowden BJ, Kreuter MH, Voth R, Muller WE (1990) Sulphoeverman, a polyanionic polysaccharide, and the narcissus lectin potently inhibit human immunodeficiency virus infection by binding to viral envelope protein. *J Gen Virol* **71**: 1957-1963.
- Witvrouw M, Fikkert V, Hantson A, Pannecouque C, O'Keefe B, McMahon J, De Clercq E, Bolmstedt A (2005) Resistance of HIV-1 to high-mannose binding agents cyanovirin N and concanavalin A. *J Virol*, in press.
- Wolbank S, Kunert R, Stiegler G, Katinger H (2003) Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. *J Virol* **77**: 4095-4103.
- Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. *Nature* **393**: 705-711.



Footnotes

The research was financially supported by the European Commission (René Descartes Prize-2001, Krediet nr. HPAW-2002-90001, and EMPRO No. 503558 of the 6<sup>th</sup> Frame Work Programme), the ANRS (France) and the Fonds voor Wetenschappelijk Onderzoek (FWO) Krediet nr. G-0267-04.

### Legends to the Figures

Fig. 1. Schedule of selection of mutant HIV-1(III<sub>B</sub>) strains that are highly resistant against the plant lectins HHA and GNA. Arrows indicate the time points where the virus isolates were made [HIV-1/GNA-500CS (dotted line); HIV-1/HHA-500CS (broken line); HIV-1/HHA-500SN (full line)]. Dotted line represents the subcultivation schedule in which for each passage cell suspensions (CS) of GNA-exposed CEM cell cultures were transferred. Broken and full-lines represent the subcultivation schedule in which for each passage, cell suspensions (CS) and supernatants (SN) of HHA-exposed CEM cell cultures were transferred.

Fig. 2. PCR-based detection of virus entry into U87.CD4.CXCR4 cells. Two hours after infection with 1000, 500 or 250 pg/ml p24 antigen of the wild-type HIV-1 III<sub>B</sub> strain [lanes 1, 2 and 3, respectively] or the plant lectin-resistant strains HIV-1/GNA-500CS [lanes 4-6], HIV-1/HHA-500CS [lanes 7-9] or HIV-1/HHA-500SN [lanes 10-12], total DNA was extracted from the cells and analyzed by semi-quantitative PCR using HIV-1-specific primers from the LTR R/U5 region. As a control, DNA samples from virus-inoculated (1000 pg/ml p24 antigen) non-susceptible U87.CD4.CCR5 cells were also included and produced no signal with the HIV-specific PCR [lane 13 : wildtype; lane 14 : HIV-1/GNA-500CS; lane 15 : HIV-1/HHA-500CS; lane 16 : HIV-1/HHA-500SN]. DNA recovery was controlled by PCR with  $\beta$ -actin-specific primers.

Fig. 3. The gp120 core structure according to Kwong et al. (1998). Panel A: A ribbon diagram (left) and topology diagram (right) are shown. Loops are labeled LA-LF and V1-V5. The 5-helices are labeled  $\alpha$ 1- $\alpha$ 5. The 25  $\beta$ -strands are shown as arrows. The viral membrane is oriented above and the target cell membrane below. The approximate location of the 12 glycosylation sites that were mutated in the plant lectin-resistant virus strains are shown as black asterixes (topology diagram (right)), or as red balls (ribbon diagram (left)). The other glycosylation sites that are not mutated in the plant lectin-resistant virus strains are indicated as yellow balls. The open circle on the V1/V2 loop at amino acid 188

represents the newly created N-glycosylation site that appeared by mutating T188 to 188N. Panel B: Ribbon diagrams showing the mutations at the glycosylation sites (red balls) in gp120 of HIV-1/GNA-500CS (top), HIV-1/HHA-500SN (middle) and HIV-1/HHA-500CS (bottom).

Structures were drawn according to MOLSCRIPT (Kraulis et al., 1991).

Table 1. Drug resistance selection against a clinical HIV-1/HE strain in the presence of escalating HHA and GNA concentrations.

| Passage number <sup>a</sup> | Compound concentration (µg/ml) |                  |                | p24 levels (ng/ml) in CEM cell cultures in the presence of following compounds |       |       |
|-----------------------------|--------------------------------|------------------|----------------|--------------------------------------------------------------------------------|-------|-------|
|                             | HHA                            | GNA              | None           | HHA                                                                            | GNA   | None  |
| 1                           | 5                              | 20               | 0              | 1,837                                                                          | 2,044 | 1,665 |
| 2                           | 10                             | 40               | 0              | 328                                                                            | 901   | 1,830 |
| 3                           | 10                             | 40               | 0              | 1,351                                                                          | 1,219 | 397   |
| 4                           | 10                             | 40               | 0              | 1,645                                                                          | 1,442 | 1,370 |
| 5                           | 25                             | 100              | 0              | 2,193                                                                          | 2,348 | 1,753 |
| 6                           | 25                             | 100              | 0              | 1,414                                                                          | 1,800 | 1,408 |
| 7                           | 50                             | 200              | 0              | 1,158                                                                          | 2,002 | 1,111 |
| 8                           | 50                             | 200              | 0              | 395                                                                            | 1,827 | 1,074 |
| 9                           | 50                             | 200              | 0              | 242                                                                            | 1,412 | 1,486 |
| 10                          | 100                            | 200              | 0              | 32                                                                             | 331   | 1,220 |
| 11                          | 100                            | 200 <sup>b</sup> | 0              | 61                                                                             | 2,041 | 1,028 |
| 12                          | 100                            |                  | 0              | 42                                                                             |       | 1,148 |
| 13                          | 100                            |                  | 0              | 25                                                                             |       | 1,394 |
| 14                          | 100                            |                  | 0              | 1,617                                                                          |       | 1,084 |
| 15                          | 100                            |                  | 0              | 2,619                                                                          |       | 1,006 |
| 16                          | 200                            |                  | 0              | 188                                                                            |       | 1,481 |
| 17                          | 200                            |                  | 0              | 6                                                                              |       | 1,254 |
| 18                          | 200                            |                  | 0              | 3                                                                              |       | 707   |
| 19                          | 200 <sup>b</sup>               |                  | 0 <sup>b</sup> | 2                                                                              |       | 1,514 |

<sup>a</sup>Subcultivations were performed every 4 or 5 days.

<sup>b</sup>Virus stock prepared for gp120 gene sequencing analysis.

Table 2. Glycosylation sites affected in HIV-1(III<sub>B</sub>) gp120 under HHA or GNA pressure in CEM cell cultures

| Glycosylated asparagines <sup>a</sup> in HIV-1(III <sub>B</sub> ) gp120 | Complex (C)- <sup>b</sup> or highly mannose (M)-type glycosylation sites | Mutations in gp120 that appeared in drug-resistant virus strains <sup>c,d</sup> |                   |                    |
|-------------------------------------------------------------------------|--------------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------|--------------------|
|                                                                         |                                                                          | HIV-1/GNA-500CS                                                                 | HIV-1/HHA-500SN   | HIV-1/HHA-500CS    |
| 88NVT90                                                                 | C                                                                        | T/I90                                                                           | I90               | -                  |
| 136NDT138                                                               | C                                                                        | -                                                                               | -                 | -                  |
| 141NSS143                                                               | C                                                                        | -                                                                               | -                 | -                  |
| 156NCS158                                                               | C                                                                        | -                                                                               | -                 | -                  |
| 160NIS162                                                               | C                                                                        | -                                                                               | -                 | -                  |
| 186NDT188                                                               | C                                                                        | -                                                                               | N188 <sup>c</sup> | -                  |
| 197NTS199                                                               | C                                                                        | -                                                                               | -                 | -                  |
| 230NKT232                                                               | M                                                                        | M232                                                                            | -                 | M232               |
| 234NGT236                                                               | M                                                                        | <u>K234</u>                                                                     | A236              | I236               |
| 241NVS243                                                               | M                                                                        | -                                                                               | -                 | -                  |
| 262NGS264                                                               | M                                                                        | -                                                                               | -                 | -                  |
| 276NFT278                                                               | C                                                                        | -                                                                               | -                 | T/I278             |
| 289NQS291                                                               | M                                                                        | <u>N/D289</u> ; S/F291                                                          | <u>K289</u>       | -                  |
| 295NCT297                                                               | M                                                                        | -                                                                               | I297              | I297               |
| 301NNT303                                                               | C                                                                        | <u>Y301</u>                                                                     | -                 | <u>Y301</u>        |
| 332NIS334                                                               | M                                                                        | -                                                                               | N334              | N334               |
| 339NNT341                                                               | M                                                                        | I341                                                                            | I341              | <u>Y339</u>        |
| 356NKT358                                                               | C                                                                        | -                                                                               | -                 | -                  |
| 386NST388                                                               | M                                                                        | -                                                                               | <u>D386</u>       | -                  |
| 392NST394                                                               | M                                                                        | I394                                                                            | -                 | <u>D392</u> ; I394 |
| 397NST399 <sup>f</sup>                                                  | C                                                                        | -                                                                               | -                 | -                  |
| 406NNT408                                                               | C                                                                        | -                                                                               | -                 | -                  |
| 448NIT450                                                               | M                                                                        | -                                                                               | -                 | -                  |
| 463NES465 <sup>g</sup>                                                  | C                                                                        | -                                                                               | -                 | -                  |

<sup>a,b</sup>Amino acid sequence numbering according to P.D. Kwong *et al.* (3) and assignment of complex- or highly mannose-type glycosylation sites according to C.K. Leonard *et al.* (2).

<sup>c</sup>Mutant HIV-1(III<sub>B</sub>) strains that emerged under stepwise escalating HHA or GNA concentrations, starting from 0.25 up to 500 µg/ml.

<sup>d</sup>Underlined mutated amino acids represent mutations at the asparagine residues that are part of a glycosylation motif. Not underlined mutated amino acids represent mutations at threonine/serine residues that are part of a glycosylation motif.

<sup>e</sup>The 188T to 188N mutation leads to destruction of the N-glycosylation site at N186 but creates a novel potential N-glycosylation site at N188 as part of the newly created glycosylation motif 188**NTS**190.

<sup>f</sup>The 397**NST**399 glycosylation site is deleted in HIV-1(III<sub>B</sub>).

<sup>g</sup>The 463**NES**465 glycosylation site does not exist in the HIV-1(III<sub>B</sub>) strain used in our experiments due to the presence of a 463**NGP**465 sequence.

Table 3. Sensitivity/resistance profile of mutant HIV-1 strains against plant lectins and other viral entry or reverse transcriptase inhibitors

| Compound          | EC <sub>50</sub> <sup>a</sup> (μg/ml) |                 |                    |                 |                    |
|-------------------|---------------------------------------|-----------------|--------------------|-----------------|--------------------|
|                   | Wild-type HIV-1(III <sub>B</sub> )    | HIV-1/HHA-500CS | fold<br>resistance | HIV-1/HHA-500SN | fold<br>resistance |
| GNA               | 0.27 ± 0.058                          | 26.7 ± 5.77     | [99] <sup>b</sup>  | 250 ± 87        | [926]              |
| HHA               | 0.21 ± 0.12                           | 55 ± 34         | [262]              | 193 ± 93        | [919]              |
| LOA               | 0.057 ± 0.021                         | 6.2 ± 3.4       | [109]              | 13 ± 6.1        | [228]              |
| CA                | 0.43 ± 0.058                          | 60.0 ± 34.6     | [140]              | ≥ 100           | [≥ 233]            |
| NPA               | 0.37 ± 0.058                          | 71 ± 38         | [192]              | ≥ 100           | [≥ 270]            |
| CV-N              | 0.015 ± 0.0058                        | 0.077 ± 0.021   | [5.1]              | 0.43 ± 0.32     | [29]               |
| DS-5000           | 0.60 ± 0.17                           | 0.50 ± 0.26     | [0.8]              | 0.60 ± 0.35     | [1]                |
| AMD3100           | 0.031 ± 0.020                         | 0.057 ± 0.006   | [1.8]              | 0.025 ± 0.013   | [0.8]              |
| T-20              | 0.038 ± 0.010                         | 0.047 ± 0.014   | [1.2]              | 0.036 ± 0.026   | [1.0]              |
| UC-781            | 0.0015 ± 0.0004                       | 0.002 ± 0.0003  | [1.3]              | 0.003 ± 0.0004  | [2.0]              |
| ( <i>R</i> )-PMPA | 1.0 ± 0.25                            | 1.3 ± 1.2       | [1.3]              | 4.1 ± 2.8       | [4.1]              |
| Mab 2G12          | 1.4 ± 0.4                             | > 25            | [> 15]             | > 25            | [> 15]             |

<sup>a</sup>50% Effective concentration, or drug concentration required to inhibit virus-induced cytopathicity in CEM cell cultures by 50%.

<sup>b</sup>Values between brackets represent the degree (fold-) of resistance of the test compounds compared with wild-type virus.

Table 4. Characterization of mutant HIV-1 strains

| Virus strain    | p24 (pg/ml) <sup>a</sup><br>(x 10 <sup>-3</sup> ) | Viral load <sup>b</sup><br>(RNA copies/ml)<br>x 10 <sup>9</sup> | Ratio viral load/p24<br>(RNA copies/pg p24 x 10 <sup>6</sup> ) | Infectivity <sup>c</sup><br>factor | Relative infectivity <sup>d</sup><br>normalized to equal p24 amounts | Relative infectivity <sup>e</sup><br>normalized to equal RNA amounts |
|-----------------|---------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------------------|
| HIV-1 (WT)      | 2,040                                             | 8,152                                                           | 4.0                                                            | 16                                 | 1                                                                    | 1                                                                    |
| HIV-1/GNA-500CS | 1,330                                             | 5,025                                                           | 3.8                                                            | 300                                | 29                                                                   | 30                                                                   |
| HIV-1/HHA-500CS | 1,100                                             | 2,794                                                           | 2.5                                                            | 60                                 | 7.0                                                                  | 11                                                                   |
| HIV-1/HHA-500SN | 4,780                                             | 15,878                                                          | 3.3                                                            | 400                                | 11                                                                   | 13                                                                   |

<sup>a</sup>Amount of HIV-1 p24 antigen in the virus stocks prepared from the supernatants of (mutant) virus-infected CEM cell cultures.

<sup>b</sup>Number of RNA copies present in the virus stocks as determined by a signal amplification nucleic acid probe assay (VERSANT HIV-1 RNA 3.0 Assay).

<sup>c</sup>Factor that is required to dilute the virus stocks to obtain equal (100%) infectivity of the cell cultures as quantified by the number of 50%-cell culture infective doses (CCID<sub>50</sub>).

<sup>d,e</sup>Calculated values relative to wild-type virus.






Fig. 1




Fig. 2





Fig. 3. Panel A






Fig. 3. Panel B